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Background. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant effects on low-density
lipoprotein (LDL) cholesterol and nonhigh density lipoprotein (HDL) cholesterol. To date, there have been limited reports on
the effect of PCSK9 inhibitors on remnant cholesterol. Objectives. Assess the effect of PCSK9 inhibitors on nonfasting remnant
cholesterol in a real world population. Identify whether pretreatment triglyceride levels are associated with PCSK9 inhibition
success as indicated by changes in remnant cholesterol levels. Methods. Patients in our adult lipid clinic (n = 109) receiving
PCSK9 inhibition for atherosclerotic cardiovascular disease or familial hypercholesterolemia who had available pre- and postPCSK9 inhibition standard nonfasting lipid data were, retrospectively, selected for data analysis. Remnant cholesterol was the
difference between non-HDL and LDL cholesterol. LDL cholesterol was measured directly and calculated from Friedewald and
Martin/Hopkins methods. Data were analyzed using repeated measures ANOVA and multivariable linear regression for differential
effects on remnant and LDL cholesterol based upon pretreatment nonfasting triglyceride levels. Results. Remnant cholesterol as well
as total, LDL, non-HDL cholesterol, and triglycerides decreased significantly (P<0.001) after PCSK9 inhibition. Patients with higher
pretreatment triglyceride levels showed greater decrease in remnant cholesterol after PCSK9 inhibition (P<0.001) than those with
lower pretreatment triglycerides. Conclusions. In patients receiving PCSK9 inhibitors, remnant cholesterol as determined from
nonfasting blood was reduced in proportion to pretreatment triglycerides.

1. Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitors have demonstrated significant effects on most
lipoprotein particles and their respective cholesterol content.
The recently completed Fourier outcomes trial demonstrated
significant reductions in low-density lipoprotein (LDL)
cholesterol, nonhigh density lipoprotein (HDL) cholesterol,
total cholesterol, Apolipoproteins B (Apo B) and A1, triglycerides, and lipoprotein a in a large population of patients
with stable coronary disease using evolocumab [1]. In earlier
efficacy trials, both alirocumab and evolocumab had been
demonstrated to lower concentrations of intermediate density cholesterol (IDL) [2, 3]. The pharmacologic reduction

of most particles that include Apo B has shown prognostic
benefit [4]. Very low-density lipoprotein (VLDL) remnants,
IDL, and chylomicron remnants contain Apo B (either
Apo B100 or 48) and are often collectively referred to as
remnant cholesterol or triglyceride-rich lipoproteins (TRL).
In fasting specimens, directly measured remnant lipoprotein
cholesterol has been demonstrated to be associated with
increased risk of coronary heart disease and large artery
atherosclerotic stroke [5, 6]. In nonfasting specimens, a
simpler method to estimate remnant cholesterol content
has also been suggested to be an independent causal risk
factor for ischemic heart disease [7]. While all patients
prescribed PCSK9 inhibitors will have unacceptably high
LDL cholesterol, all patients prescribed PCSK9 inhibitors
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will not necessarily have elevated remnant cholesterol or
triglycerides.
To date, there are limited reports on the effect of PCSK9
inhibitors on remnant cholesterol [2, 3]. The purpose of this
study was to evaluate the effect of these medications on
nonfasting remnant cholesterol in a real world population of
patients with FDA- and payer-approved clinical indications
for the medication and to confirm that the effect of PCSK9
inhibition on remnant cholesterol is dependent upon the
baseline triglyceride level.

2. Materials and Methods
2.1. Patient Population. All patients were >18 years of age
and referred to our adult lipid clinic at the West Virginia University Heart and Vascular Institute because of
an unacceptably high LDL cholesterol level. All patients
had either atherosclerotic cardiovascular disease (ASCVD)
or heterozygous familial hypercholesterolemia (FH) without
clinical ASCVD as qualifying diagnoses for approval of
PCSK9 inhibitors. The vast majority of patients had some
adjustment made to their lipid-lowering therapy upon arrival
to the lipid clinic. However, all patients were on a stable
regimen of lipid-lowering therapy at the time of enrollment
and use of the PCSK9 inhibitor. No changes in lipid-lowering
therapy were made during the initiation and follow-up of the
PCSK9 inhibitor. All patients received approval from their
respective payers for the administration of the particular
PCSK9 inhibitor that was acceptable to the payer. Criteria
used were the patient’s qualifying diagnosis, documented
record of lipid-lowering therapy, and current lipid levels on
that therapy. All patients had unacceptably high LDL cholesterol levels on the maximal medical therapy they were able
to tolerate, meaning that their LDL cholesterol levels were
>70 mg/dl for ASCVD and >100 mg/dl for FH. Patients could
be on moderate to high-intensity statin therapy, completely
statin intolerant on 0 mg of statin, tolerant of small doses
of statin, on other nonstatin therapies, or some combination
of these. All patients included in this analysis had standard
nonfasting lipid laboratory data available just before administration and after the administration of at least 3 doses of
the PCSK9 inhibitor. Dosing interval for PCSK9 inhibitors
was biweekly. All patients received either evolocumab or
alirocumab. Approval to use patient data was obtained from
the institutional review board and a waiver of consent was
granted.
2.2. Laboratory Testing. All patients had nonfasting lipid
testing. Standard lipid measurements were performed on
ARCHITECT c-analyzers using ARCHITECT reagents
(Abbott Diagnostics, Abbott Park, IL, USA) including
measured lipid profile components (total cholesterol,
HDL cholesterol, and triglycerides) and direct LDL
measurements at baseline (pretreatment) and minimally
after the third dose of PCSK9 inhibitor. An attempt
was also made to obtain Apo B measurements before
and after therapy. Total cholesterol measurements were
performed using standard enzymatic assay employing
coupled cholesterol esterase/cholesterol oxidase reactions
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and detection of quinoneimine product at 500 nm. HDL
cholesterol measurements were performed employing
selective dissolution of HDL with proprietary detergent and
subsequent coupled cholesterol esterase/cholesterol oxidase
reactions as for total cholesterol measurement. Triglycerides
measurements were performed using standard enzymatic
assay employing coupled lipase/glycerol kinase/glycerol
phosphate oxidase reactions and detection of quinoneimine
product at 500 nm. Direct LDL cholesterol measurements
were performed employing selective dissolution of LDL
with proprietary detergent and subsequent coupled
cholesterol esterase/cholesterol oxidase reactions as for
total cholesterol measurement. Apo B measurements were
performed at a reference laboratory using the Tina-quant
Apolipoprotein B immunoturbidimetric assay (Roche
Diagnostics, Indianapolis, IN, USA).
2.3. Calculations. Remnant cholesterol was determined by
calculating the difference between non-HDL cholesterol
and LDL cholesterol as previously described [7]. Non-HDL
cholesterol was determined by calculating the difference
between total cholesterol and HDL cholesterol. In addition
to the direct measurement, LDL cholesterol was calculated using 2 methods: Friedewald equation (LDL = total
cholesterol – HDL cholesterol – (triglycerides/5)) [8] and
the recently described Martin/Hopkins method [8]. Because
the Friedewald equation and Martin/Hopkins method both
fail when triglycerides are > 400 mg/dL, the direct LDL
measurement was substituted.
2.4. Statistical Analysis. All analyses were performed with
SPSS Statistics Version 24.0 (IBM Corp., Armonk, NY). P
value < 0.05 was considered statistically significant. Continuous variables were presented as mean ± standard deviation
(SD) and categorical variables were presented as frequency
(percent). Pretreatment to posttreatment lipid measures were
compared using paired-samples 𝑡 tests. Pearson correlations
were conducted to compare changes in remnant cholesterol
with changes in other lipid measures. To examine the impact
of pretreatment triglyceride levels on change in remnant
cholesterol measures, groups were created above and below
the median value of pretreatment triglycerides in this sample
(>223 versus ≤223). Changes in LDL and remnant cholesterol
by pretreatment triglyceride groups were examined using
repeated measures ANOVA. Multivariable linear regression
analyses were used to examine the impact of pretreatment
triglyceride groups on change in remnant cholesterol measures after adjustment for age, gender, diabetes, ASCVD, any
statin use, and type/dose of PCSK9 inhibitor (evolocumab
140 mg, alirocumab 75 mg, and alirocumab 150 mg). Beta
and B coefficient values are presented from these models to
show the standardized and unstandardized estimate of effect,
respectively, in remnant cholesterol change for each factor
in the model, although only factors significantly associated
with remnant cholesterol change were interpreted. The B
coefficients can be used to form the regression equation for
each model and represent the estimate of effect for each
variable using the original units of measurement, whereas
the beta coefficient is standardized and can demonstrate the
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Table 1: Baseline characteristics of patient sample.
Total Sample
N = 109

Age (years)
Female
PCSK9 Inhibitor
Evolocumab 140mg
Alirocumab 75mg
Alirocumab 150 mg
ASCVD
Coronary
Peripheral
Cerebral
Polyvascular
Coronary calcium
FH without ASCVD
Diabetes
Lipid diagnosis ASCVD
Hypercholesterolemia alone
Combined hyperlipidemia
Therapy
ASCVD
FH

64.1 ± 11.7
65 (60)
62 (57)
23 (21)
24 (22)
98 (90)
87
2
1
2
6
11 (10)
37 (34)

Statin Intolerance
78 (80)
9 (82)

61 (56)
37 (34)
Any Statin
20 (20)
2 (18)

Any LLRx
44 (45)
2 (18)

ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LLRx, lipid lowering therapy; PCSK9, proprotein convertase subtilisin kexin
9.
Data presented as frequency (%) or mean ± SD.

relative strength of effect amongst all factors in the model
regardless of differing units of measurement.
It is possible that the phenomenon of regression to the
mean could play a role in the results of this study given
that there was only one pretreatment measurement and
one posttreatment measurement. Therefore, for the purpose
of sensitivity analyses, an equation was used to estimate
the regression to the mean effect [9] and doubly robust
ANCOVA analyses of the triglyceride group effect on change
in remnant cholesterol levels, adjusted again by baseline
remnant cholesterol levels, were conducted.

3. Results
3.1. Patient Population. Between September 2015 and January
2018, 122 patients were treated with PCSK9 inhibitors. At the
time of this analysis, 10 patients had not received 3 doses
of drug and had not obtained follow-up lipid profiles. Three
additional patients failed to get adequate follow-up lipid
profiles after beginning medication. Therefore, 109 patients
had lipid profile data before and after PCSK9 inhibition,
including 62 patients with evolocumab and 47 patients with
alirocumab (Table 1). Most patients were treated because
of ASCVD (mean age = 65.4 ± 10.4 years). Most with
ASCVD had statin intolerance, hypercholesterolemia alone,
and coronary artery disease as the principle manifestation
and were not on any lipid-lowering therapy. Of the 10%

of patients who had familial hypercholesterolemia without
ASCVD (mean age = 52.0 ± 15.6 years), most had statin
intolerance, pure hypercholesterolemia (n = 1 with combined
hyperlipidemia) and were not on any lipid-lowering therapy.
Diabetes of any type was present in 34% of patients, all with
ASCVD.
3.2. Basic Lipid Data. With the exception of HDL cholesterol, all lipid measures decreased significantly after PCSK9
inhibition (Table 2). Examining continuous variable change
scores, greater absolute decrease in triglycerides after PCSK9
inhibition was significantly correlated with greater absolute
decrease in remnant cholesterol when LDL was derived using
any of the 3 methods (Friedewald equation [r = 0.87, P <
0.001], Martin/Hopkins method [r = 0.77, P < 0.001], and
direct measurement [r = 0.71, P < 0.001]). The absolute
decrease in remnant cholesterol was significantly greater
when LDL was derived by Martin/Hopkins method than
when derived by Friedewald equation (–14.3 versus –11.7, P =
0.002) or measured directly (–14.3 versus –10.99, P = 0.022).
3.3. Impact of Pretreatment Triglyceride Levels. Repeated
measures ANOVA revealed that patients in the high pretreatment triglyceride group (n = 54) had greater reductions in
remnant cholesterol than patients in the low pretreatment
triglyceride group (n = 55) regardless of the way LDL was
determined (Friedewald equation [F = 20.0, P < 0.001], direct
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Table 2: Lipid levels before and after treatment.

Total cholesterol
HDLc
NonHDLc
Triglycerides
LDLc
Friedewald equation
Direct measurement
Martin/Hopkins method
Remnant cholesterol
Friedewald equation LDLc
Direct measurement LDLc
Martin/Hopkins method LDLc
Apolipoprotein B (n = 98)

Pre-treatment
259.6 ± 70.1
45.1 ± 11.3
215.1 ± 68.6
255.3 ± 161.7

Post-treatment
151.5 ± 52.7
46.0 ± 11.8
106.5 ± 52.4
191.9 ± 99.8

% Change
–41%
2%
–50%
–24%

P value
<0.001
0.228
<0.001
<0.001

167.0 ± 57.2
174.5 ± 57.2
171.3 ± 56.4

70.11 ± 47.2
76.9 ± 46.4
76.9 ± 46.0

–58%
–56%
–55%

<0.001
<0.001
<0.001

48.1 ± 28.2
40.6 ± 29.9
43.8 ± 27.2
141.4 ± 40.8

36.4 ± 16.5
29.6 ± 15.4
29.6 ± 13.1
74.2 ± 30.5

–24%
–27%
–32%
–48%

<0.001
<0.001
<0.001
<0.001

HDLc = high density lipoprotein cholesterol, LDLc = low density lipoprotein cholesterol.

measurement [F = 11.4, P = 0.001], and Martin/Hopkins
method [F = 16.9, P < 0.001]; Figure 1). Repeated measures
ANOVA also revealed that patients in the high pretreatment
triglyceride group had similar reductions in Friedewald
derived LDL (F = 0.3, P = 0.591), direct measurement LDL
(F = 1.2, P = 0.275), and Martin/Hopkins derived LDL (F =
1.0, P = 0.315) to patients in the low pretreatment triglyceride
group (Figure 2).
In multivariable analyses, pretreatment triglycerides
group (low versus high) was a significant independent factor
associated with changes in remnant cholesterol after PCSK9
inhibition (Table 3). Specifically, patients in the high pretreatment triglyceride group had greater reductions in remnant cholesterol regardless of the way LDL was determined
(Friedewald equation [B = −20.1, P < 0.001], Martin/Hopkins
method [B = −16.8, P < 0.001], and direct measurement [B
= −16.3, P = 0.001]). Within these multivariable models, the
high pretreatment triglyceride group was associated with a
20.1 point, 16.8 point, and 16.3 point greater reduction in
remnant cholesterol, respectively, when LDL was determined
by Friedewald equation, Martin/Hopkins method, and direct
measurement. Multivariable analyses also demonstrated that
the type of drug used was significantly associated with
changes in remnant cholesterol when LDL was derived with
the Friedewald equation and Martin/Hopkins method, but
not when direct LDL measurement was utilized. Specifically, patients who received alirocumab 150 mg had greater
reductions in remnant cholesterol than patients who received
evolocumab 140 mg when LDL was derived by the Friedewald
equation (B = −12.1, P = 0.036) and Martin/Hopkins method
(B = −12.8, P = 0.015). Within these multivariable models,
alirocumab 150 mg was associated with a 12.1-point and 12.8point greater reduction in remnant cholesterol compared to
evolocumab 140 mg when LDL was derived by Friedewald
equation and Martin/Hopkins method, respectively.
The results of sensitivity analysis estimates found that
it is possible that the change in remnant cholesterol levels
for the low triglyceride group was mostly due to regression
to the mean, but the change in remnant cholesterol levels

for the high triglyceride group had an effect over and
above the effect for regression to the mean. In addition,
doubly robust ANCOVA analyses found similar effects for
triglyceride group as the primary univariate analyses in the
study (Friedewald equation [F = 3.8, P = 0.055], direct
measurement [F = 4.9, P = 0.029], and Martin/Hopkins
method [F = 5.3, P = 0.023]).

4. Discussion
This study demonstrates that remnant cholesterol, like all
other Apo B containing lipid fractions, is effectively lowered
by PCSK9 inhibition. Importantly, these observations were
made in a real world population outside of a clinical trial.
In addition, as expected, our findings demonstrate that the
degree of remnant cholesterol lowering by PCSK9 inhibition
is associated with pretreatment triglyceride concentration,
although the same is not true for LDL cholesterol lowering.
This finding is consistent with the concept that remnant
cholesterol containing larger TRL particles is predicted to be
elevated when the serum triglycerides are elevated.
While all of the study patients had approved indications
for PCSK9 inhibition, most were not treated with highintensity statins and thus were considered to be statin
intolerant. As a result, pretreatment LDL cholesterol was
significantly higher in our study patients than those seen
in clinical trials [1]. When compared with the results of the
Fourier study [1], the percent decrease in nonHDL, Apo B,
and LDL cholesterol in our study was comparable. However,
the percent decrease in triglycerides was greater in our
study, likely reflecting the nonfasting lipid testing and higher
pretreatment triglyceride levels.
We used 3 different methods to generate LDL cholesterol
results and then subsequent remnant cholesterol results.
Each of the 3 methodologies has strengths and weaknesses.
The commonly calculated and nearly universal Friedewald
method should not be used when triglycerides are >
400 mg/dL; in such instances, direct LDL measurement is
preferred. The recently described Martin/Hopkins method
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Figure 1: Change in remnant cholesterol levels from pretreatment to posttreatment by pretreatment triglyceride groups (error bars: 95% CI).

[8] utilizes the same measured variables as the Friedewald
method. However, when rapid ultracentrifugation is used as
the standard, the Martin/Hopkins method is more accurate
than the Friedewald method in estimate of LDL cholesterol
especially when the LDL levels are low [10]. Nevertheless,
the Martin/Hopkins method still has the limitation when
triglycerides are > 400 mg/dL. Direct LDL measurement
is not dependent on the measurement of triglycerides for
its determination and should not be effected by elevated
triglycerides as are the other 2 methods. In fact in the current
study, the pretreatment direct LDL was higher than the LDLs
estimated by the other 2 methods perhaps reflecting the
absence of the triglyceride influence. While directly measured
LDL has none of the aforementioned limitations due to
triglycerides, it is not as standardized as are the measurements
in the standard lipid profile (total cholesterol, HDL, and
triglycerides) used to calculate LDL cholesterol. The effect of
PCSK9 inhibition on LDL and remnant cholesterol is qualitatively similar using each of the 3 methods. The quantitative

differences we may have found in this study will need to be
reevaluated using a larger sample size.
Current knowledge concerning how PCSK9 inhibitors
work indicates that the interaction between LDL particles and
the LDL receptor is effected by PCSK9 such that the LDL
receptor (as well as the LDL particle) is ultimately destroyed
and never recycled back to the hepatic cellular surface.
Remnant particles have a somewhat different pathway for
clearance [11]; as the larger TRL particles such as VLDL have
their triglyceride content reduced by lipase hydrolysis, they
eventually become IDL or smaller VLDL particles. Given
sufficient time, they can eventually become LDL particles.
Most TRL particles have Apolipoprotein E (Apo E) as well as
Apo B on their surfaces, acquired during the process of VLDL
production in the liver. Apo E is a ligand for the LDL receptor
in the liver as well as for hepatic heparan sulfate proteoglycan
receptors (HSPG-R). HSPG-R contain hepatic lipase and
polypeptide strands used to capture lipoproteins. Due to configurational issues, many VLDL remnants cannot bind to LDL
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Figure 2: Change in LDL cholesterol levels from pretreatment to posttreatment by pretreatment triglyceride groups (error bars: 95% CI).

receptors and must rely on HSPG-R for remnant clearance.
Remnant particles become attached to HSPG-R via Apo E
binding and undergo further triglyceride lipolysis by hepatic
lipase. By this mechanism, many remnant particles diminish
in size and become LDL particles suitable for clearance by the
LDL receptor. Recent information [12] suggests that, in addition to being involved in remnant metabolism, HSPG-R are
PCSK9 receptors that facilitate subsequent PCSK9 and LDL
receptor complex formation. Much like the interference with
LDL clearance, this PCSK9/LDL receptor complex formation
would interfere with the process of remnant clearance as well,
due to the reduction in available LDL receptors as VLDL and
IDL become LDL particles. Therefore, it would be expected
that PCSK9 inhibition by currently available monoclonal
antibodies would facilitate the process of remnant as well as
LDL clearance.
The differences found by multivariable analysis concerning the effect of equipotent doses of 2 PCSK9 inhibitors on
the reduction of remnant cholesterol may be related to sample

size or chance alone. Thus, further study in larger groups of
patients is needed.
4.1. Study Limitations. This study is limited by its lack of
a control group, small sample size, lack of specific remnant particle analysis, and direct measurement of remnant
cholesterol content. Previously published data involved 81
healthy, normolipemic, nonobese men for evolocumab [2],
and 18 healthy volunteers for alirocumab [3]. Evolocumab
significantly reduced remnant pool size and increased the
fractional catabolic rate of IDL and VLDL [2]. Alirocumab
significantly reduced IDL cholesterol content but not VLDL
cholesterol content [3]. Larger pools of more clinically relevant patients with appropriate control groups are available
from the Fourier [1] (evolocumab, N = 27,564), Spire [13]
(bococizumab, N = 27,438), and Odyssey [14] (alirocumab,
N = 18,924) outcomes trials. It is unclear whether these
large datasets have detailed remnant particle data or directly
measured remnant cholesterol as used in prior studies
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Table 3: Results of the multivariable linear regression analyses for change in remnant cholesterol when LDL was derived by 3 different
methodologies.
Friedewald Equation
Age
Female
Diabetes
ASCVD
Statin
Alirocumab 75mg vs evolocumab 140mg
Alirocumab 150mg vs evolocumab 140mg
Triglyceride group (high vs low)
Direct Measurement
Age
Female
Diabetes
ASCVD
Statin
Alirocumab 75mg vs evolocumab 140mg
Alirocumab 150mg vs evolocumab 140mg
Triglyceride group (high vs low)
Martin/Hopkins Method
Age
Female
Diabetes
ASCVD
Statin
Alirocumab 75mg vs evolocumab 140mg
Alirocumab 150mg vs evolocumab 140mg
Triglyceride group (high vs low)

B
–0.21
8.79
–5.25
0.87
–2.45
–8.39
–12.09
–20.06

Beta
–0.10
0.18
–0.10
0.01
–0.04
–0.14
–0.21
–0.41

P Value
0.708
0.074
0.278
0.913
0.669
0.156
0.036
<0.001

–0.31
8.39
–1.61
2.90
–8.60
–1.56
–7.29
–16.29

–0.14
0.16
–0.03
0.04
–0.14
–0.03
–0.12
–0.32

0.193
0.113
0.757
0.734
0.165
0.806
0.236
0.001

–0.27
8.62
–4.16
1.15
–0.87
–6.04
–12.76
–16.76

–0.14
0.19
–0.09
0.02
–0.02
–0.11
–0.24
–0.38

0.185
0.053
0.342
0.872
0.866
0.259
0.015
<0.001

ASCVD = atherosclerotic cardiovascular disease.

[5, 6, 15]. Nevertheless, the analysis of remnant cholesterol
and risk as presented by Varbo et al. [7] suggests that the
simple calculation of remnant cholesterol from non-HDL
cholesterol minus LDL cholesterol could be sufficient to
assess clinical impact. These simpler remnant cholesterol data
are available in the 3 large randomized trial populations and
could be explored to confirm the findings of our study and
determine whether these changes in remnant cholesterol have
a prognostic impact independent of the effect on LDL.
We limited our evaluation to nonfasting specimens principally for the sake of patient convenience. However, the
use of nonfasting lipids is endorsed by numerous societies,
guidelines, and statements including the American Heart
Association, the European Society of Cardiology, and the
American Association of Clinical Endocrinology [16]. In
addition, Varbo et al. [7] have demonstrated through both
observational hazard assessments and Mendelian randomization studies that nonfasting remnant cholesterol assessments
using the simpler calculation have merit as a means to assess
for an effect on clinical outcomes.
4.2. Summary. In this real world population receiving PCSK9
inhibition for approved indications and using nonfasting

lipid measurements, all Apo B containing particle subgroups
had significant reductions in their respective cholesterol
concentrations, including remnants. Remnant cholesterol
was estimated by the simple subtraction of LDL cholesterol
from non-HDL cholesterol. As anticipated, those patients
with higher pretreatment triglyceride levels and therefore
higher levels of pretreatment remnant cholesterol had a
greater decrease in remnant cholesterol after treatment than
patients with relatively normal pretreatment triglyceride and
remnant levels. Further study in larger populations and
with more measurement points will be needed to confirm
these findings and determine if these findings will have
independent prognostic significance.

Data Availability
The data used to support the findings of this study are
available from the corresponding author upon request.
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